JB&ZJMY HOLDING COMPANY INCORPORATED (OTCMKTS:JBZY) had an increase of 18.59% in short interest. JBZY’s SI was 191,400 shares in February as released by FINRA. Its up 18.59% from 161,400 shares previously. The stock increased 1.67% or $0.0006 during the last trading session, reaching $0.0347. About shares traded. JB&ZJMY Holding Company, Inc. (OTCMKTS:JBZY) has 0.00% since February 14, 2017 and is . It has underperformed by 16.70% the S&P500.
Among 12 analysts covering Audentes Thera… (BOLD), 9 have Buy rating, 0 Sell and 3 Hold. Therefore 75% are positive. Audentes Thera… has $56.0 highest and $20 lowest target. $34.44’s average target is 7.59% above currents $32.01 stock price. Audentes Thera… had 19 analyst reports since August 15, 2016 according to SRatingsIntel. The stock of Audentes Therapeutics, Inc. (NASDAQ:BOLD) has “Hold” rating given on Monday, February 12 by Mizuho. H.C. Wainwright maintained the stock with “Buy” rating in Wednesday, February 7 report. The firm earned “Overweight” rating on Monday, August 15 by PiperJaffray. As per Thursday, October 12, the company rating was initiated by Raymond James. Leerink Swann maintained it with “Buy” rating and $29.0 target in Wednesday, November 15 report. H.C. Wainwright maintained Audentes Therapeutics, Inc. (NASDAQ:BOLD) on Thursday, January 11 with “Buy” rating. The rating was initiated by Wedbush with “Outperform” on Monday, August 15. Bank of America maintained the stock with “Buy” rating in Friday, September 22 report. The company was maintained on Thursday, January 4 by William Blair. The rating was downgraded by Evercore on Monday, October 16 to “In-Line”.
The stock decreased 2.41% or $0.79 during the last trading session, reaching $32.01. About 154,307 shares traded. Audentes Therapeutics, Inc. (BOLD) has 0.00% since February 14, 2017 and is . It has underperformed by 16.70% the S&P500.
Audentes Therapeutics, Inc., a biotechnology company, focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects in the United States. The company has market cap of $1.17 billion. The firm is developing AT132 for the treatment of X-linked myotubular myopathy; AT342 for the treatment of crigler-najjar syndrome type 1; AT982 for the treatment of pompe disease; and AT307 for the treatment of the CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia. It currently has negative earnings. Audentes Therapeutics, Inc. has a collaboration with the University of Pennsylvania for the treatment of Crigler-Najjar.
Analysts await Audentes Therapeutics, Inc. (NASDAQ:BOLD) to report earnings on March, 8. They expect $-0.93 earnings per share, down 2.20% or $0.02 from last year’s $-0.91 per share. After $-0.88 actual earnings per share reported by Audentes Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 5.68% negative EPS growth.